Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Liver Cancer

HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Liver Cancer: Clinical Trial

Outcome
Finished, no results posted
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
May 2015
Ended
February 2016
Enrollment
87 participants
Sites
1
Primary outcomes
Number of participants with Adverse events
Sponsor type
Academic / other
Results posted
No
Last update
25 February 2016

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA) for liver cancer.

Detailed description public domain (ClinicalTrials.gov)

By enrolling patients with liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA) for liver cancer.